Novel combination markers for predicting survival in patients with muscle invasive bladder cancer: USP18 and DGCR2

Journal of Korean Medical Science

Volumn 29, Issue 3, 2014, Pages 351-356

  Kim, Ye Hwan ^a   Kim, Won Tae ^a   Jeong, Pildu ^a   Ha, Yun Sok ^a,d   Kang, Ho Won ^a   Yun, Seok Joong ^a   Moon, Sung Kwon ^b   Choi, Yung Hyun ^c   Kim, Isaac Yi ^d   Kim, Wun Jae ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Chung Ang University   (South Korea)

^c Dong Eui University   (South Korea)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

DGCR2; Gene expression profiling; Human; Survival; Urinary bladder neoplasms; USP18 protein

Indexed keywords

ADHESION RECEPTOR; BIOLOGICAL MARKER; CARRIER PROTEIN; PROTEINASE; THROMBIN RECEPTOR; USP18 PROTEIN, HUMAN; ZNF699 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER STAGING; DGCR2; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MUSCLE TUMOR; PATHOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; RISK FACTOR; SURVIVAL; TUMOR INVASION; VERY ELDERLY;

DGCR2; GENE EXPRESSION PROFILING; SURVIVAL; URINARY BLADDER NEOPLASMS; USP18 PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARRIER PROTEINS; ENDOPEPTIDASES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; RISK FACTORS; ROC CURVE; URINARY BLADDER NEOPLASMS;

EID: 84902536808     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2014.29.3.351     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Ghoneim MA, AbdelLatif M, elMekresh M, AbolEnein H, Mosbah A, Ashamallah A, elBaz MA. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008; 180: 121-7.
3. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-22.
4. Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137-49.
5. Türkölmez K, Tokgöz H, Reşorlu B, Köse K, Bedük Y. Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors. Urology 2007; 70: 477-81.
6. Shim UJ, Lee IS, Kang HW, Kim J, Kim WT, Kim IY, Ryu KH, Choi YH, Moon SK, Kim YJ, et al. Decreased DBC1 expression is associated with poor prognosis in patients with non-muscle-invasive bladder cancer. Korean J Urol 2013; 54: 631-7.
7. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354: 2463-72.
8. Gyorffy B, Benke Z, Lánczky A, Balázs B, Szállási Z, Timár J, Schäfer R. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 2012; 132: 1025-34.
9. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res 2012; 18: 1323-33.
10. Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC, Kim IY, Moon SK, Um HD, Choi YH. A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med 2011; 17: 478-85.
11. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, PalouRedorta J; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14.
12. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002; 87: 13-5.
13. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-25.
14. Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350: 1828-37.
15. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-26.
16. Youssef RF, Lotan Y. Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. ScientificWorldJournal 2011; 11: 369-81.
17. Bochner BH, Kattan MW, Vora KC, International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006; 24: 3967-72.
18. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol 2006; 176: 1354-61.
19. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009; 182: 78-84.
20. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007; 8: 128-36.
21. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010; 183: 1744-50.
22. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006; 98: 1090-3.
23. Kang HW, Yoon HY, Ha YS, Kim WT, Kim YJ, Yun SJ, Lee SC, Kim WJ. FAM70B as a novel prognostic marker for cancer progression and cancer-specific death in muscle-invasive bladder cancer. Korean J Urol 2012; 53: 598-606.
24. Baek KH. Conjugation and deconjugation of ubiquitin regulating the destiny of proteins. Exp Mol Med 2003; 35: 1-7.
25. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002; 277: 9976-81.
26. Duex JE, Comeau L, Sorkin A, Purow B, Kefas B. Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. J Biol Chem 2011; 286: 25377-86.
27. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37: S9-15.
28. Taylor C, Wadey R, O'Donnell H, Roberts C, Mattei MG, Kimber WL, WynshawBoris A, Scambler PJ. Cloning and mapping of murine Dgcr2 and its homology to the Sez-12 seizure-related protein. Mamm Genome 1997; 8: 371-5.
29. McDonaldMcGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore) 2011; 90: 1-18.
30. Shifman S, Levit A, Chen ML, Chen CH, Bronstein M, Weizman A, Yakir B, Navon R, Darvasi A. A complete genetic association scan of the 22q11 deletion region and functional evidence reveal an association between DGCR2 and schizophrenia. Hum Genet 2006; 120: 160-70.